Format

Send to

Choose Destination
Genet Med. 2019 Mar;21(3):631-640. doi: 10.1038/s41436-018-0129-y. Epub 2018 Aug 10.

The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants.

Author information

1
Albert Einstein College of Medicine and the Children's Hospital at Montefiore, Bronx, New York, USA. mwassers@montefiore.org.
2
Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, New York, USA.
3
New York University School of Medicine and NYU Langone Health, New York, New York, USA.
4
Icahn School of Medicine at Mount Sinai and the Mount Sinai Medical Center, New York, New York, USA.
5
Albert Einstein College of Medicine and the Children's Hospital at Montefiore, Bronx, New York, USA.
6
Maimonides Medical Center, Brooklyn, New York, USA.
7
New York City Health and Hospitals/Elmhurst, Queens, New York, USA.

Abstract

PURPOSE:

We conducted a consented pilot newborn screening (NBS) for Pompe, Gaucher, Niemann-Pick A/B, Fabry, and MPS 1 to assess the suitability of these lysosomal storage disorders (LSDs) for public health mandated screening.

METHODS:

At five participating high-birth rate, ethnically diverse New York City hospitals, recruiters discussed the study with postpartum parents and documented verbal consent. Screening on consented samples was performed using multiplexed tandem mass spectrometry. Screen-positive infants underwent confirmatory enzymology, DNA testing, and biomarker quantitation when available. Affected infants are being followed for clinical management and long-term outcome.

RESULTS:

Over 4 years, 65,605 infants participated, representing an overall consent rate of 73%. Sixty-nine infants were screen-positive. Twenty-three were confirmed true positives, all of whom were predicted to have late-onset phenotypes. Six of the 69 currently have undetermined disease status.

CONCLUSION:

Our results suggest that NBS for LSDs is much more likely to detect individuals at risk for late-onset disease, similar to results from other NBS programs. This work has demonstrated the feasibility of using a novel consented pilot NBS study design that can be modified to include other disorders under consideration for public health implementation as a means to gather critical evidence for evidence-based NBS practices.

KEYWORDS:

newborn screening; pilot newborn screen; lysosomal storage disorders; informed consent

Comment in

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center